Lung cancer
6 trials- 2020ADAURAEGFR adjuvantIn 682 patients with completely resected stage IB–IIIA EGFR-mutated NSCLC, three years of adjuvant osimertinib improved disease-free and overall survival compared with placebo.
- 2020CROWNALK-rearranged NSCLCIn 296 patients with untreated advanced ALK-positive NSCLC, lorlatinib improved progression-free survival and intracranial response compared with crizotinib.
- 2018FLAURAEGFR-mutant NSCLCIn 556 patients with untreated EGFR-mutated advanced NSCLC, osimertinib improved progression-free and overall survival compared with first-generation EGFR-TKI (gefitinib or erlotinib).
- 2017PACIFICStage III NSCLCIn 713 patients with unresectable stage III NSCLC and no progression after concurrent chemoradiation, durvalumab consolidation for one year improved progression-free and overall survival compared with placebo.
- 2016KEYNOTE-024NSCLC immunotherapyIn 305 patients with stage IV NSCLC and PD-L1 TPS ≥50%, no EGFR/ALK alterations, pembrolizumab improved progression-free and overall survival compared with platinum-doublet chemotherapy.
- 2009IPASSEGFR-mutant NSCLCIn 1,217 Asian, never/light-smoker patients with advanced lung adenocarcinoma, gefitinib improved progression-free survival in the EGFR-mutation-positive subgroup compared with carboplatin + paclitaxel.